BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications of various company’s RORgt modulators have appeared in the last several months. Chemically, 251 is interesting with 5 stereocenters, none of which look [...]
< 1 minute read
Sep. 17, 2021
BMS-986251: A Selective RORgt Inverse Agonist
BMS-986251
selective RORgt inverse agonist entered clinical dev. (psoriasis), discontinued from HTS and SBDD ACS Med. Chem. Lett., Apr. 10, 2020 Bristol Myers Squibb, Princeton, NJ